Unconventional myosin-Ig [Cleaved into: Minor histocompatibility antigen HA-2 (mHag HA-2)]
1_MEDEE 6_ GPEYG 11_ KPDFV 16_ LLDQV 21_ TMEDF 26_ MRNLQ 31_ LRFEK 36_ GRIYT 41_ YIGEV 46_ LVSVN 51_ PYQEL 56_ PLYGP 61_ EAIAR 66_ YQGRE 71_ LYERP 76_ PHLYA 81_ VANAA 86_ YKAMK 91_ HRSRD 96_ TCIVI 101_ SGESG 106_ AGKTE 111_ ASKHI 116_ MQYIA 121_ AVTNP 126_ SQRAE 131_ VERVK 136_ DVLLK 141_ STCVL 146_ EAFGN 151_ ARTNR 156_ NHNSS 161_ RFGKY 166_ MDINF 171_ DFKGD 176_ PIGGH 181_ IHSYL 186_ LEKSR 191_ VLKQH 196_ VGERN 201_ FHAFY 206_ QLLRG 211_ SEDKQ 216_ LHELH 221_ LERNP 226_ AVYNF 231_ THQGA 236_ GLNMT 241_ VHSAL 246_ DSDEQ 251_ SHQAV 256_ TEAMR 261_ VIGFS 266_ PEEVE 271_ SVHRI 276_ LAAIL 281_ HLGNI 286_ EFVET 291_ EEGGL 296_ QKEGL 301_ AVAEE 306_ ALVDH 311_ VAELT 316_ ATPRD 321_ LVLRS 326_ LLART 331_ VASGG 336_ RELIE 341_ KGHTA 346_ AEASY 351_ ARDAC 356_ AKAVY 361_ QRLFE 366_ WVVNR 371_ INSVM 376_ EPRGR 381_ DPRRD 386_ GKDTV 391_ IGVLD 396_ IYGFE 401_ VFPVN 406_ SFEQF 411_ CINYC 416_ NEKLQ 421_ QLFIQ 426_ LILKQ 431_ EQEEY 436_ EREGI 441_ TWQSV 446_ EYFNN 451_ ATIVD 456_ LVERP 461_ HRGIL 466_ AVLDE 471_ ACSSA 476_ GTITD 481_ RIFLQ 486_ TLDMH 491_ HRHHL 496_ HYTSR 501_ QLCPT 506_ DKTME 511_ FGRDF 516_ RIKHY 521_ AGDVT 526_ YSVEG 531_ FIDKN 536_ RDFLF 541_ QDFKR 546_ LLYNS 551_ TDPTL 556_ RAMWP 561_ DGQQD 566_ ITEVT 571_ KRPLT 576_ AGTLF 581_ KNSMV 586_ ALVEN 591_ LASKE 596_ PFYVR 601_ CIKPN 606_ EDKVA 611_ GKLDE 616_ NHCRH 621_ QVAYL 626_ GLLEN 631_ VRVRR 636_ AGFAS 641_ RQPYS 646_ RFLLR 651_ YKMTC 656_ EYTWP 661_ NHLLG 666_ SDKAA 671_ VSALL 676_ EQHGL 681_ QGDVA 686_ FGHSK 691_ LFIRS 696_ PRTLV 701_ TLEQS 706_ RARLI 711_ PIIVL 716_ LLQKA 721_ WRGTL 726_ ARWRC 731_ RRLRA 736_ IYTIM 741_ RWFRR 746_ HKVRA 751_ HLAEL 756_ QRRFQ 761_ AARQP 766_ PLYGR 771_ DLVWP 776_ LPPAV 781_ LQPFQ 786_ DTCHA 791_ LFCRW 796_ RARQL 801_ VKNIP 806_ PSDMP 811_ QIKAK 816_ VAAMG 821_ ALQGL 826_ RQDWG 831_ CRRAW 836_ ARDYL 841_ SSATD 846_ NPTAS 851_ SLFAQ 856_ RLKTL 861_ QDKDG 866_ FGAVL 871_ FSSHV 876_ RKVNR 881_ FHKIR 886_ NRALL 891_ LTDQH 896_ LYKLD 901_ PDRQY 906_ RVMRA 911_ VPLEA 916_ VTGLS 921_ VTSGG 926_ DQLVV 931_ LHARG 936_ QDDLV 941_ VCLHR 946_ SRPPL 951_ DNRVG 956_ ELVGV 961_ LAAHC 966_ QGEGR 971_ TLEVR 976_ VSDCI 981_ PLSHR 986_ GVRRL 991_ ISVEP 996_ RPEQP 1001_ EPDFR 1006_ CARGS 1011_FTLLW
1: Unconventional myosin required during immune response for detection of rare antigen-presenting cells by regulating T-cell migration. Unconventional myosins are actin-based motor molecules with ATPase activity and serve in intracellular movements. Acts as a regulator of T-cell migration by generating membrane tension, enforcing cell-intrinsic meandering search, thereby enhancing detection of rare antigens during lymph-node surveillance, enabling pathogen eradication. Also required in B-cells, where it regulates different membrane/cytoskeleton-dependent processes. Involved in Fc-gamma receptor (Fc-gamma-R) phagocytosis
2: Constitutes the minor histocompatibility antigen HA-2. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and their expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. HA-2 is restricted to MHC class I HLA-A*0201